Correlation between p14ARF/p16INK4A expression and HPV infection in uterine cervical cancer

Cancer Letters

Volumn 213, Issue 1, 2004, Pages 31-37

  Kanao, Hiroyuki ^a   Enomoto, Takayuki ^a   Ueda, Yutaka ^a   Fujita, Masami ^a   Nakashima, Ryuichi ^a   Ueno, Yuko ^a   Miyatake, Takashi ^a   Yoshizaki, Tatsuo ^a   Buzard, Gregory S ^b   Kimura, Toshihiro ^a   Yoshino, Kiyoshi ^a   Murata, Yuji ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b SAIC FREDERICK INC   (United States)

Author keywords

Cervical cancer; Human papillomavirus; p14ARF; p16INK4A

Indexed keywords

PROTEIN P14; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA PRIMERS; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RETINOBLASTOMA PROTEIN; RISK FACTORS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRUS;

EID: 4344630263     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.03.030     Document Type: Article

References (28)

1. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J. Clin. 49:1999;33-64
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:1999;12-19
3. Stoler M.H. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int. J. Gynecol. Pathol. 19:2000;16-28
4. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr. Top. Microbiol. Immunol. 186:1994;131-156
5. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 75:1993;495-505
6. Chellappan S., Kraus V.B., Kroger B., Munger K., Howley P.M., Phelps W.C., Nevins J.R. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc. Natl Acad. Sci. USA. 89:1992;4549-4553
7. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:1994;753-756
8. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440
9. Quelle D.E., Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:1995;993-1000
10. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:1998;725-734
11. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707
12. Zhang H.S., Postigo A.A., Dean D.C. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell. 97:1999;53-61
13. Eymin B., Gazzeri S., Brambilla C., Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene. 21:2002;2750-2761
14. Sharpless N.E., DePinho R.A. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9:1999;22-30
15. Nakashima R., Fujita M., Enomoto T., Haba T., Yoshino K., Wada H., et al. Alteration of p16 and p15 genes in human uterine tumours. Br. J. Cancer. 80:1999;458-467
16. Nuovo G.J., Plaia T.W., Belinsky S.A., Baylin S.B., Herman J.G. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc. Natl Acad. Sci. USA. 96:1999;12754-12759
17. Sano T., Oyama T., Kashiwabara K., Fukuda T., Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am. J. Pathol. 153:1998;1741-1748
18. Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U., et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int, J Cancer. 92:2001;276-284
19. Pecorelli S., Benedet J.L., Creasman W.T., Shepherd J.H. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int. J. Gynaecol. Obstet. 64:1999;5-10
20. Fujinaga Y., Shimada M., Okazawa K., Fukushima M., Kato I., Fujinaga K. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J. Gen. Virol. 72:(Pt 5):1991;1039-1044
21. Bates S., Phillips A.C., Clark P.A., Stott F., Peters G., Ludwig R.L., Vousden K.H. p14ARF links the tumour suppressors RB and p53. Nature. 395:1998;124-125
22. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., Palmero I., Ryan K., Hara E., Vousden K.H., Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. Eur. Mol. Biol. Org. J. 17:1998;5001-5014
23. Malanchi I., Caldeira S., Krutzfeldt M., Giarre M., Alunni-Fabbroni M., Tommasino M. Identification of a novel activity of human papillomavirus type 16 E6 protein in deregulating the G1/S transition. Oncogene. 21:2002;5665-5672
24. Giarre M., Caldeira S., Malanchi I., Ciccolini F., Leao M.J., Tommasino M. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle arrest. J. Virol. 75:2001;4705-4712
25. Milde-Langosch K., Riethdorf S., Kraus-Poppinghaus A., Riethdorf L., Loning T. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch. 439:2001;55-61
26. Gasco M., Sullivan A., Repellin C., Brooks L., Farrell P.J., Tidy J.A., et al. Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia. Oncogene. 21:2002;1876-1881
27. Gasco M., Bell A.K., Heath V., Sullivan A., Smith P., Hiller L., et al. Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res. 62:2002;2072-2076
28. Wong Y.F., Chung T.K., Cheung T.H., Nobori T., Yu A.L., Yu J., Batova A., Lai K.W., Chang A.M. Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett. 136:1999;231-235